Qiagen NV reported net sales of $532.6 million for the three months ended September 30, 2025, an increase from $501.9 million in the same period of 2024. Gross profit for the quarter was $331.3 million, up from $308.3 million the previous year. For the nine-month period ended September 30, 2025, net sales reached $1,549.6 million, compared to $1,457.0 million in 2024. As of September 30, 2025, Qiagen employed approximately 5,700 people across more than 35 locations and serves over 500,000 customers worldwide in Life Sciences and Molecular Diagnostics. The company continues to focus on sample to insight solutions, including sample technologies, assay technologies, bioinformatics, and automation solutions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.